Tags

Type your tag names separated by a space and hit enter

Bioconversion of α-linolenic acid into n-3 long-chain polyunsaturated fatty acid in hepatocytes and ad hoc cell culture optimisation.
PLoS One. 2013; 8(9):e73719.Plos

Abstract

This study aimed to establish optimal conditions for a cell culture system that would allow the measurement of 18:3n-3 (ALA) bioconversion into n-3 long-chain polyunsaturated fatty acid (n-3 LC-PUFA), and to determine the overall pathway kinetics. Using rat hepatocytes (FaO) as model cells, it was established that a maximum 20:5n-3 (EPA) production from 50 µM ALA initial concentration was achieved after 3 days of incubation. Next, it was established that a gradual increase in the ALA concentration from 0 up to 125 µM lead to a proportional increase in EPA, without concomitant increase in further elongated or desaturated products, such as 22:5n-3 (DPA) and 22:6n-3 (DHA) in 3 day incubations. Of interest, ALA bioconversion products were observed in the culture medium. Therefore, in vitro experiments disregarding the medium fatty acid content are underestimating the metabolism efficiency. The novel application of the fatty acid mass balance (FAMB) method on cell culture system (cells with medium) enabled quantifying the apparent enzymatic activities for the biosynthesis of n-3 LC-PUFA. The activity of the key enzymes was estimated and showed that, under these conditions, 50% (Km) of the theoretical maximal (V max = 3654 µmol.g(-1) of cell protein.hour(-1)) Fads2 activity on ALA can be achieved with 81 µM initial ALA. Interestingly, the apparent activity of Elovl2 (20:5n-3 elongation) was the slowest amongst other biosynthesis steps. Therefore, the possible improvement of Elovl2 activity is suggested toward a more efficient DHA production from ALA. The present study proposed and described an ad hoc optimised cell culture conditions and methodology towards achieving a reliable experimental platform, using FAMB, to assist in studying the efficiency of ALA bioconversion into n-3 LC-PUFA in vitro. The FAMB proved to be a powerful and inexpensive method to generate a detailed description of the kinetics of n-3 LC-PUFA biosynthesis enzymes activities in vitro.

Authors+Show Affiliations

School of Life and Environmental Sciences, Deakin University, Victoria, Australia.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24040040

Citation

Alhazzaa, Ramez, et al. "Bioconversion of Α-linolenic Acid Into N-3 Long-chain Polyunsaturated Fatty Acid in Hepatocytes and Ad Hoc Cell Culture Optimisation." PloS One, vol. 8, no. 9, 2013, pp. e73719.
Alhazzaa R, Sinclair AJ, Turchini GM. Bioconversion of α-linolenic acid into n-3 long-chain polyunsaturated fatty acid in hepatocytes and ad hoc cell culture optimisation. PLoS ONE. 2013;8(9):e73719.
Alhazzaa, R., Sinclair, A. J., & Turchini, G. M. (2013). Bioconversion of α-linolenic acid into n-3 long-chain polyunsaturated fatty acid in hepatocytes and ad hoc cell culture optimisation. PloS One, 8(9), e73719. https://doi.org/10.1371/journal.pone.0073719
Alhazzaa R, Sinclair AJ, Turchini GM. Bioconversion of Α-linolenic Acid Into N-3 Long-chain Polyunsaturated Fatty Acid in Hepatocytes and Ad Hoc Cell Culture Optimisation. PLoS ONE. 2013;8(9):e73719. PubMed PMID: 24040040.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bioconversion of α-linolenic acid into n-3 long-chain polyunsaturated fatty acid in hepatocytes and ad hoc cell culture optimisation. AU - Alhazzaa,Ramez, AU - Sinclair,Andrew J, AU - Turchini,Giovanni M, Y1 - 2013/09/11/ PY - 2013/04/03/received PY - 2013/07/23/accepted PY - 2013/9/17/entrez PY - 2013/9/17/pubmed PY - 2014/7/6/medline SP - e73719 EP - e73719 JF - PloS one JO - PLoS ONE VL - 8 IS - 9 N2 - This study aimed to establish optimal conditions for a cell culture system that would allow the measurement of 18:3n-3 (ALA) bioconversion into n-3 long-chain polyunsaturated fatty acid (n-3 LC-PUFA), and to determine the overall pathway kinetics. Using rat hepatocytes (FaO) as model cells, it was established that a maximum 20:5n-3 (EPA) production from 50 µM ALA initial concentration was achieved after 3 days of incubation. Next, it was established that a gradual increase in the ALA concentration from 0 up to 125 µM lead to a proportional increase in EPA, without concomitant increase in further elongated or desaturated products, such as 22:5n-3 (DPA) and 22:6n-3 (DHA) in 3 day incubations. Of interest, ALA bioconversion products were observed in the culture medium. Therefore, in vitro experiments disregarding the medium fatty acid content are underestimating the metabolism efficiency. The novel application of the fatty acid mass balance (FAMB) method on cell culture system (cells with medium) enabled quantifying the apparent enzymatic activities for the biosynthesis of n-3 LC-PUFA. The activity of the key enzymes was estimated and showed that, under these conditions, 50% (Km) of the theoretical maximal (V max = 3654 µmol.g(-1) of cell protein.hour(-1)) Fads2 activity on ALA can be achieved with 81 µM initial ALA. Interestingly, the apparent activity of Elovl2 (20:5n-3 elongation) was the slowest amongst other biosynthesis steps. Therefore, the possible improvement of Elovl2 activity is suggested toward a more efficient DHA production from ALA. The present study proposed and described an ad hoc optimised cell culture conditions and methodology towards achieving a reliable experimental platform, using FAMB, to assist in studying the efficiency of ALA bioconversion into n-3 LC-PUFA in vitro. The FAMB proved to be a powerful and inexpensive method to generate a detailed description of the kinetics of n-3 LC-PUFA biosynthesis enzymes activities in vitro. SN - 1932-6203 UR - https://www.unboundmedicine.com/medline/citation/24040040/Bioconversion_of_α_linolenic_acid_into_n_3_long_chain_polyunsaturated_fatty_acid_in_hepatocytes_and_ad_hoc_cell_culture_optimisation_ L2 - http://dx.plos.org/10.1371/journal.pone.0073719 DB - PRIME DP - Unbound Medicine ER -